Kura Oncology (KURA) Profit After Tax (2010 - 2026)
Kura Oncology (KURA) reported Profit After Tax of -$73.3 million for Q1 2026, down 27.69% year-over-year from -$101.4 million in Q1 2025, and up 9.46% quarter-over-quarter from -$81.0 million in Q4 2025.
Kura Oncology (KURA) Profit After Tax (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 17 years of Profit After Tax data on file, last reported at -$73.3 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$73.3 million, down 27.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$294.6 million (down 61.95% YoY), and the FY2025 annual result was -$278.7 million, down 60.17% from the prior year.
- Profit After Tax improved to -$73.3 million in Q1 2026 per KURA's latest filing, from -$81.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$19.2 million in Q4 2024 and troughed at -$81.0 million in Q4 2025.
- A 5-year average of -$47.9 million and a median of -$42.8 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 55.09% in 2024, then tumbled 321.5% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$33.1 million in 2022, then slipped by 29.21% to -$42.8 million in 2023, then soared by 55.09% to -$19.2 million in 2024, then plunged by 321.5% to -$81.0 million in 2025, then advanced by 9.46% to -$73.3 million in 2026.
- Business Quant data shows KURA's Profit After Tax at -$73.3 million in Q1 2026, -$81.0 million in Q4 2025, and -$74.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -73.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.33 Mn |
| Dec 31, 2025 | -81.00 Mn |
| Sep 30, 2025 | -74.12 Mn |
| Jun 30, 2025 | -66.12 Mn |
| Mar 31, 2025 | -57.43 Mn |
| Dec 31, 2024 | -19.22 Mn |
| Sep 30, 2024 | -54.40 Mn |
| Jun 30, 2024 | -50.84 Mn |
| Mar 31, 2024 | -49.53 Mn |
| Dec 31, 2023 | -42.79 Mn |
| Sep 30, 2023 | -38.60 Mn |
| Jun 30, 2023 | -37.17 Mn |
| Mar 31, 2023 | -34.07 Mn |
| Dec 31, 2022 | -33.11 Mn |
| Sep 30, 2022 | -35.50 Mn |
| Jun 30, 2022 | -34.77 Mn |
| Mar 31, 2022 | -32.45 Mn |
| Dec 31, 2021 | -32.74 Mn |
| Sep 30, 2021 | -33.37 Mn |
| Jun 30, 2021 | -33.66 Mn |